Business Model & Revenue
FutureFuel operates two integrated segments from a single Batesville, Arkansas manufacturing complex. The Chemicals segment is a custom and performance specialty chemicals contract manufacturer, producing proprietary agrochemicals, adhesion promoters, biocide intermediates, and antioxidant precursors for specific industrial customers under multi-year agreements. Performance chemicals include nylon and polyester polymer modifiers and specialty solvents. The business model is capital-light: customers increasingly fund capacity expansions dedicated to their programs, as demonstrated by the $25M commitment in 2026 and up to $17M in 2027.
The Biofuels segment produces biodiesel from a flexible feedstock platform with approximately 59 million gallons of annual nameplate capacity, making FutureFuel the largest biodiesel producer in the southeastern United States. Revenue depends on production volumes, feedstock costs (primarily soybean oil), and finished biodiesel prices, which are influenced by Renewable Fuel Standard obligations and the 45Z Clean Fuel Production Credit. The segment also generates revenue from the monetization of Section 45Z and Small Producer Tax Credits through third-party agreements.
The integrated Batesville site provides a competitive advantage: shared infrastructure, utilities, logistics, and technical expertise across both segments enable cost efficiencies that standalone operators cannot match. The company's 100% domestic production footprint positions it to benefit from reshoring trends as customers seek to localize supply chains.
Financial Highlights
Q2 2026 Results vs Prior Year
| Metric | Q2 2026 | Q2 2025 | YoY |
|---|---|---|---|
| Revenue | $78.7M | $35.7M | +120.6% |
| Gross Profit | $15.0M | $(12.4)M | nm |
| Gross Margin | 19.1% | nm | nm |
| Net Income (Loss) | $11.4M | $(14.2)M | nm |
| EPS (Diluted) | $0.25 | $(0.32) | nm |
| Adjusted EBITDA | $11.8M | $(11.4)M | nm |
Quarterly Progression
| Quarter | Revenue | Net Income (Loss) | EPS (Diluted) | Gross Margin |
|---|---|---|---|---|
| Q2 2026 | $78.7M | $11.4M | $0.25 | 19.1% |
| Q1 2026 | $32.0M | $(20.6)M | $(0.47) | nm |
| Q4 2025 | $19.8M | $(12.0)M | $(0.27) | nm |
| Q3 2025 | $22.7M | $(5.1)M | $(0.12) | nm |
Segment Breakdown (Q2 2026)
| Segment | Revenue | YoY Growth | Gross Profit | Utilization |
|---|---|---|---|---|
| Chemicals | $25.8M | +55.5% | $5.0M | 65% |
| Biofuels | $52.9M | +177.5% | $10.1M | 56% |
Balance Sheet (June 30, 2026)
| Item | Amount |
|---|---|
| Cash and Equivalents | $34.4M |
| Total Debt | $0.0M |
| Revolver Available | $35.0M |
| Shareholders' Equity | $153.1M |
| Shares Outstanding | 43.9M |
Guidance: Full-year 2026 positive Adjusted EBITDA (excluding non-cash derivative timing). $22M in 45Z tax credit monetization proceeds expected in H2 2026. Q3 biofuel production expected to exceed Q2 levels.
Competitive Landscape
FutureFuel competes in two distinct markets with different competitive sets. In specialty chemicals, the company is a small but differentiated contract manufacturer serving energy, agricultural, and industrial end markets. In biofuels, it is a pure-play biodiesel producer benefiting from U.S. renewable fuel mandates.
-
Eastman Chemical (EMN): Large-cap specialty chemicals competitor with broad portfolio. FutureFuel competes for custom chemical contracts where dedicated U.S. production capacity and technical synthesis expertise are differentiators. Eastman's scale advantages are offset by FutureFuel's agility and customer-funded capacity model.
-
Huntsman Corporation (HUN): Diversified chemicals manufacturer with overlapping end markets. Huntsman's scale provides cost advantages, but FutureFuel wins on flexibility and willingness to dedicated-build for individual customers.
-
Innospec (IOSP): Specialty chemicals company with fuel additives and performance chemicals. Closer in scale to FutureFuel and competes for similar contract manufacturing opportunities.
-
Rex American Resources (REX): Biofuels producer with ethanol focus. The closest public biofuel comp, though different fuel type. Both benefit from U.S. renewable fuel mandates but serve different regional and product markets.
-
Stepan Company (SCL): Specialty and performance chemicals manufacturer. Larger than FutureFuel but competes in similar custom synthesis and surfactant markets.
Competitive moats include: (1) integrated Batesville complex with 30+ years of chemical manufacturing expertise, providing cost and operational advantages; (2) largest biodiesel production capacity in the southeastern U.S. with 59M gallon nameplate; (3) 100% domestic production footprint positioning for reshoring demand; (4) customer-funded capacity expansion model reducing capital intensity; and (5) dual-segment diversification smoothing single-market volatility.
Catalysts
-
Q3 2026 earnings (expected November 2026): Management indicated Q3 biofuel production will exceed Q2's 8.4M gallons. A second consecutive profitable quarter would confirm the inflection is sustainable.
-
$22M tax credit monetization: The 45Z Clean Fuel Production and Small Producer Tax Credit agreement is expected to deliver approximately $3M in Q3 and $19M in Q4 2026, providing meaningful cash inflow without dilution.
-
Customer-funded capacity expansion: $25M in 2026 and up to $17M in 2027 from an existing chemicals customer to fund new production capacity coming online in early fiscal 2028, validating the contract manufacturing value proposition.
-
Biofuel regulatory tailwinds: EPA's 2026-2027 RVO mandates set record renewable volume obligations, creating a multi-year demand floor for domestic biodiesel production. Any further regulatory clarity could accelerate utilization beyond the current 56%.
-
Chemical capacity utilization upside: At 65% utilization with 12% more capacity than a year ago, the chemicals segment has significant operating leverage remaining. New customer program wins could push utilization above 75% and drive margin expansion.
Key Risks
- Q2 results benefited from a $9.1M derivative timing recovery tied to biofuel hedging; core quarterly gross profit excluding this effect was approximately $5.9M, still improved but less dramatic than headline figures suggest
- Biofuel profitability depends heavily on the EPA's Renewable Fuel Standard mandates and the 45Z Clean Fuel Production Credit; any rollback or delay in renewable fuel policy would materially impact the segment
- Chemicals segment capacity utilization at 65% leaves significant room for improvement but also indicates that roughly one-third of nameplate capacity remains idle, weighing on fixed cost absorption
- Input costs for soybean oil and other biofuel feedstocks remain elevated and could compress margins if finished biodiesel prices weaken before hedging positions adjust
- Small scale (43.9M shares, under $300M market cap) and limited sell-side coverage create liquidity risk and potential for sharp price reversals if quarterly results disappoint
Our Thesis
FutureFuel spent 2025 in a deep trough. Full-year revenue of $95.7M produced a $49.4M net loss as biofuel margins collapsed under regulatory uncertainty and chemical demand softened. Q2 2026 marks the inflection point: both segments are now generating positive gross profit, production volumes are up 40% year-over-year, and management is guiding to full-year Adjusted EBITDA positivity. The biofuel recovery is driven by structural regulatory tailwinds — the EPA's 2026-2027 RVO mandates and the 45Z Clean Fuel Production Credit create a multi-year floor on domestic biodiesel economics. On the chemicals side, a new performance chemicals customer (ramping since Q4 2025) drove 209% segment revenue growth, and a $25M customer-funded capacity expansion signals durable demand. Tax credit monetization adds $22M of H2 cash, effectively self-funding growth capex.
Our $8.00 price target is based on 12x our FY2026E Adjusted EBITDA estimate of $25M (H1 $5M plus stronger H2 driven by biofuel ramp, tax credit proceeds, and chemical utilization gains), yielding $300M EV, plus $34M net cash equals $334M equity, or $7.61 per share. We round to $8.00 to account for upside optionality from the 2027 capacity expansion and potential biofuel volume acceleration. At $6.20, FF trades at 1.2x TTM revenue and under 11x forward EBITDA — a discount that does not reflect the earnings trajectory.
Get reports like this delivered free
New small-cap research every week. No paywall, no fluff.